{"entity":{"id":"nct03383458","kind":"trial","name":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","aka":[],"tldr":"A phase 3 trial of Nivolumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation is a phase 3 interventional study registered as NCT03383458 by Bristol-Myers Squibb, with 545 participants enrolled, started 2018-04-18 and due to reach its primary completion in 2026-05-27. Interventions recorded: Nivolumab, Placebo. Conditions listed: Hepatocellular Carcinoma, Liver Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03383458","url":"https://clinicaltrials.gov/study/NCT03383458"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03383458","phase":"3","setting":"A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","sponsor":"Bristol-Myers Squibb","enrolled":545,"outcomes":[]},"route":"/trials/nct03383458/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}